Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation

Journal of Thrombosis and Thrombolysis

Volumn 42, Issue 4, 2016, Pages 573-578

  Khan, Fatima ^a   Huang, Hans ^a   Datta, Yvonne H ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Apixaban; Atrial fibrillation; Bleeding; Dabigatran; Direct oral anticoagulants; Elderly; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DRUG SAFETY; EPISTAXIS; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; VAGINA BLEEDING; VERY ELDERLY; CHEMICALLY INDUCED; HEMORRHAGE; INCIDENCE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; RETROSPECTIVE STUDIES;

EID: 84982095325     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-016-1410-z     Document Type: Article

References (22)

1. Go AS et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285(18):2370–2375
2. Reiffel JA (2014) Atrial fibrillation and stroke: epidemiology. Am J Med 127(4):e15–e16
3. Suarez Fernandez C et al (2015) Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord 15:143
4. Connolly SJ et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151
5. Patel MR et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891
6. Granger CB et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992
7. Giugliano RP et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104
8. Halperin JL et al (2014) Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 130(2):138–146
9. Eikelboom JW et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123(21):2363–2372
10. Halvorsen S et al (2014) Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 35(28):1864–1872
11. Lip GY et al (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 57(2):173–180
12. Schulman S et al (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694
13. Mant J et al (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Lancet 370(9586):493–503
14. Scowcroft AC, Lee S, Mant J (2013) Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the general practice research database (GPRD) 2000-2009. Heart 99(2):127–132
15. Rosenman MB et al (2012) Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. Curr Med Res Opin 28(9):1407–1414
16. Sharma M et al (2015) Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 132(3):194–204
17. Ng KH et al (2016) Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing 45(1):77–83
18. Camm AJ et al (2016) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 37(14):1145–1153
19. Tamayo S et al (2015) Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 38(2):63–68
20. Abraham NS et al (2015) Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 350:h1857
21. Pasca S et al (2015) Direct oral anticoagulants for very elderly people with atrial fibrillation: efficacy and safe enough? Clin Appl Thromb Hemost. doi:10.1177/1076029615619485
22. Gladstone DJ et al (2015) How to monitor patients receiving direct oral anticoagulants for stroke prevention in atrial fibrillation: a practice tool endorsed by thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society. Ann Intern Med 163(5):382–385